Dziadkowiec et al. HCA Healthcare Journal of Medicine (2020) 1:3
https://doi.org/10.36518/2689-0216.1094

Education
Improving the Quality and Design of
Retrospective Clinical Outcome Studies that
Utilize Electronic Health Records
Oliwier Dziadkowiec, PhD,1-3 Jeffery Durbin, MS,2 Vignesh Jayaraman Muralidharan, MS, ME,1
Megan Novak, MA,3 Brendon Cornett, MPH3

Author affiliations are listed
at the end of this article.
Correspondence to:
Oliwier Dziadkowiec, Ph.D.
HCA Healthcare, Graduate

Abstract

Medical Education

Description

4900 S Monaco St

Electronic health records (EHRs) are an excellent source for secondary data analysis. Studies
based on EHR-derived data, if designed properly, can answer previously unanswerable
clinical research questions. In this paper we will highlight the benefits of large retrospective
studies from secondary sources such as EHRs, examine retrospective cohort and case-control study design challenges, as well as methodological and statistical adjustment that can
be made to overcome some of the inherent design limitations, in order to increase the generalizability, validity and reliability of the results obtained from these studies.
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Background

Electronic health records (EHRs) have primarily
been developed to allow for more efficient and
complete medical billing. Secondary “core functions” of EHRs, as defined by National Academy
of Medicine, include: (1) health information, (2)
result management, (3) order entry/management, (4) decision support, (5) communication and connectivity, (6) patient support, (7)
administrative processes and reporting and (8)
population health management.1
The use of de-identified EHR patient health
information for research and quality improvement has become more frequent in the last
ten years. EHRs’ longitudinal encounter structure and extensive laboratory and pharmacy
logs make EHRs an attractive data source for
potentially impactful and inexpensive clinical
outcomes and effectiveness research studies.
Additionally, EHRs are also a major source of
data used in Comparative Effectiveness Research, an important component of the Patient
Protection and Affordable Care Act of 2010.2,3

Although there are significant benefits to big
retrospective datasets obtained from EHR
systems, designing studies that overcome
the challenges associated with retrospective
cohort and case-control design remain an issue
that undermine the generalizability, validity and
reliability of results of these otherwise meaningful studies.

The Benefits of Large Retrospective Studies Based on Electronic
Health Records and Other Retrospective Data Sources

The benefits and potential impact of data
derived from the EHR are clear in some recent, large retrospective studies. Kaelber et al.4
accumulated EHR data on more than 1.2 million
pediatric patients stemming from 196 ambulatory clinics from 27 states across the country.
The large dataset obtained from EHRs allowed
the researchers to investigate which antihyper-
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tensive medications were commonly prescribed
within the pediatric population, an analysis that
was previously underpowered and simply not
possible due to a low frequency of pediatric patients being prescribed this type of medication.
In a retrospective cohort study, Izurieta et al.5
utilized retrospective data from 2.5 million
Medicare beneficiaries ages 65 and older.
Influenza vaccination and infection rates
were pulled from administrative records, i.e.
Healthcare Common Procedure Coding System
(HCPCS) or a Current Procedural Terminology
(CPT). For the first time and due to the large
sample size, researchers were able to show
a significant decrease in hospital admissions
when patients were given the high-dose
influenza vaccination compared to patients
given the standard dose. These findings were
not shown in previous randomized studies
and can ultimately help physicians when
recommending influenza vaccinations in senior
patients.
Another population-based retrospective cohort
study looked at data from US claims and an
integrated laboratory database.6 The study
sample included 72,738 newly treated patients
with type 2 diabetes who were employed and
were commercially insured from all 50 states
in the United States. The data was de-identified, and the variables that were pulled from
the database encompassed the following: (1)
administrative and demographic data (i.e. type
of insurance plan, sex, age, dates of eligibility, and income), (2) inpatient and outpatient
visits, (3) medical procedures, (4) laboratory
tests and results, and (5) pharmacy claims. This
was the first large retrospective cohort study
to assess the comparative effectiveness and
safety of the medication sitagliptin in type 2
diabetic patients. By having thorough clinical
data to parse, this study could assist healthcare
personnel to provide safer care to patients and
more reliable prescribing of medications.6
A retrospective observational study looked
at stroke/systemic embolism (SE) and major
bleeds (MB) in patients with non-valvular atrial
fibrillation. This study comprised of 434,046
patients who were matched in six different
medicine cohorts. The data was received from
the Centers for Medicare and Medicaid Services and 4 US commercial claims databases.
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This was the largest observational study that
compared oral anticoagulants (NOAC) to the
oral drug warfarin. After analyzing the data,
findings were consistent with previous studies when comparing NOACs and warfarin.
This study offers more information regarding
the benefits and risks of stroke prevention in
nonvalvular atrial fibrillation patients due to
greater statistical power and improved generalizability from multiple databases, instead of
using a single data source like small randomized
control trials (RCTs) have previously done.7
A recent retrospective analysis used de-identified WoundExpert EHRs from 242 wound
care facilities across the US over a 5-year span.
There were a total of 1,498 patients pulled from
the EHRs, and data of 1,622 diabetic foot ulcers
(DFUs) were analyzed. Variables that were extracted from the EHRs included the following:
(1) age, (2) sex, (3) race, (4) body mass index
(BMI), (5) wound location, (6) wound size and
duration, (7) number of wounds per patient
and (8) single/multiple wounds per patient.
The researchers found significant differences in
frequency and the time of healing when using
human fibroblast-derived dermal substitute
(HFDS) in patients with diabetic foot ulcers.
These findings could imply overall cost savings
for medical resources, home health, prescription drugs, physician office visits, emergency
department visits and hospitalizations.8

Bias in the Design of Retrospective EHR-Based Research Studies

High-quality observational studies can generate credible evidence of intervention effects,
particularly when rich data are already available.
Retrospective observational studies are useful,
particularly when RCTs are not feasible and
too expensive to carry out.9 One of the major
methodological issues and challenges of retrospective observational study design includes
cohort selection bias. This bias arises when the
study population is not randomly selected from
the target population, contains loss of information, including follow-ups, drop outs or deaths
and/or an inability to control confounders that
might be associated with outcome.10
Another major limitation of retrospective study
designs is the scope of the already collected
data. In research that utilized EHR-derived
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data, most of the data were originally collected for other purpose (ex. billing) and not all
relevant information is available for analysis,
lead to omission of crucial confounders that
can introduce bias. For instance, if BMI is an important confounder in a given study and a large
percentage of patient data are missing height
or weight, the researcher might not be able
to use BMI in the analysis. In addition, when
conducting case-control or cohort studies,
omitted details from the patient’s side (ex. specific information collected from patients about
treatment episodes that involved multiple
treatments) and uncaptured patient characteristics introduce recall and selection biases.11, 12
Considering necessary sample size and power
to avoid random errors, defining a clear hypothesis, identifying correct populations and
treatments with clinically relevant data, maintaining strict inclusion criteria and exclusion
criteria, identifying and defining the outcomes
that will be used to measure for the study and
preparing a suitable study plan in advance will
help to minimize risk of research design-related
biases.13

The Role of Statistical Methods
in Reducing Bias in Retrospective
Studies

In the previous sections, the many benefits
and limitations of using EHRs for retrospective
research, such as cohort, case-control and comparative-effectiveness studies, were reviewed.
In particular, the many ways bias and error can
exist in retrospectively-collected data presents
significant challenges in using statistical methods to test trends in the population. These
challenges often take the form of missing data,
leading to a non-holistic representation of a
patient encounter. Additional challenges may
arise with incorrect data that was transcribed
during the billing process or when patient
records are entered into database systems.
Furthermore, the design of studies using this
data often suffer from a lack of randomization,
such that patient populations are not randomly selected or assigned to cohorts. When
a lack of randomization exists in the design,
confounding and selection bias may be nearly
impossible to account for in the data, such as
when patient characteristics aren’t balanced
a priori, particularly when data are missing. In

this section, we’ll review these issues in detail
and propose a selection of statistical analyses
that aid in accounting for them.

Statistical Issues in EHRs and Retrospective Studies

Missing data in EHRs can arise from a variety of
sources, ranging from a lack of documentation
to a mistake in transcription, and can prevent
researchers from having a holistic view of the
patient encounter.14, 15 Depending on the nature
of the missingness (i.e., the method in which
the data are missing), there exists a number
of statistical methods that allow us to estimate observations of the patient encounter
based on previously observed and complete
data.16 The nature of the missing data can be
categorized in three ways: missing completely
at random (MCAR), missing at random (MAR)
and missing not at random (MNAR). MCAR and
MAR circumstances are instances when data
are missing due to unknown circumstances or
when other data can explain why a datum is
missing. For example, if a physician forgets to
order a certain lab test randomly or a physician does not order one test in lieu of another,
these circumstances illustrate MCAR or MAR
data respectively. MNAR circumstances are
defined as instances when data are missing in
a mechanistic and explainable way, such as not
ordering any tests because a hospital laboratory is closed for renovations. When data are
missing at random, as in the MAR and MCAR
circumstances, methods such as imputation
and data reduction may be used to generate
possible values to replace the missing values.
In imputation methods, the goal is to generate
“likely” data values via single-value replacement
(e.g., substituting the observed mean of the
available data for the missing values) or likelihood-based methods (e.g., calculating the
most-probable value from predicted values of
a regression model). In instances where data
are MNAR, such as when patient records are
mechanistically not reported, current guidance
is to either eliminate observations with the
missing values or to remove the variable from
consideration. It is worth noting, however, that
the removal of observations can often lead to
a detrimental drop in power for a given analysis within a study, which removes valuable
information relevant to cohort or case-control
identities of the patients. Thus, it should only
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be used when few patient records are missing
the data in question.17, 18
Unfortunately, missingness is not the only
issue with retrospectively-collected EHR data.
When using these data for studies, such as
cohort, case-control or comparative-effectiveness, these designs often suffer from a lack of
randomization. Randomization refers to the
method in which data was obtained—for example, in RCTs, patients are randomly identified/
selected and randomly assigned to a cohort
relevant to the study aims. In retrospective
studies, however, patients are typically not randomly selected nor are they randomly assigned
to cohorts. In fact, the use of retrospective
data to these ends typically results in selection or ascertainment bias, as the data are the
result of non-random health care processes,
such as standards-of-care and extant protocols
for illness or disease treatment.19, 20 This lack
of randomization presents several problems:
first, many parametric statistical methods rely
on randomly-collected data as an assumption
for observing trends in the population, thus
decreasing the validity and reliability of the
tested effects and marring the true relationships inherent in the population; and second,
non-randomized data prevents the balancing
of nuisance variables or confounders between
cohorts, thus, one cohort can suffer from extraneous circumstances over another.
One possible remedy for this lack of randomization is to simulate “randomness in selection”
by randomly subsetting the available EHR
data into discrete datasets and treating them
as separate samples of the population—this
provides an opportunity to both satisfy the
randomization assumption of parametric statistical methods (thereby increasing the validity
and reliability of the test if the same effects
are observed across samples), as well as potentially to balance third-variables such that they
are contributing equal variances within and
between cohorts and across samples. While
this method provides opportunities to address
the shortcomings that a lack of randomization introduces, this cannot be done when the
available data are limited in size and scope (e.g.,
studying a low-prevalence disease entity). Fortunately, there are statistical methods that can
aid in creating balanced cohorts or identifying
nuisance variables that may be confounding the
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results of the analysis.

Selected Statistical Methods
for Studies with Retrospective
Designs

When random subsetting of a large dataset is
not suitable to simulate randomization (e.g.,
when the sample is small), the goal becomes
defining well-balanced cohorts and identifying
nuisance variables that can be accounted for
between cohorts. Hlatky et al.21 outlined two
classes of analyses that are designed to accomplish these two goals: first, the use of propensity score matching, a technique of determining an individual patient’s propensity to receive
one treatment over another, to define cohorts;
and second, the use of structural modeling and
graph-analytic approaches to identify correlational and causal relationships between variables that may indirectly influence relationships
between variables pursuant to the study aims.
In addition to these methods, data reduction
techniques, such as principal components
analysis, independent components analysis
and multidimensional scaling may be used to
extract the relevant observations and variables
that maximize explainable differences between
cohorts. Both approaches are reviewed below.

Propensity Score Matching

Propensity score matching (PSM) is a method
of using available variables, both those relevant
to the study aims, as well as possible confounders, to determine a patient’s propensity for
receiving one form of treatment over another
in order to create balanced cohorts.22, 23 Consider, for example, the examination of treatments
for a low-prevalence disease—because few
patients are diagnosed and treated for such a
disease, they may have wide variability in health
traits or symptomology. It would be impossible to compare different treatment options
without the influence of these varying traits,
and thus our analysis of the data must take
into account these traits to determine how
they influence the treatment. In its simplest
form, PSM allows researchers to balance these
nuisance traits across groups by determining
how they influence the propensity to receive a
particular treatment. Typically, the propensity
score is calculated as the prediction of a linear
combination of known variables—in most cases,
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the treatment cohorts serve as the outcome
of a generalized linear model (such as logit or
probit models) where known variables serve as
predictors. By using a nominal outcome for the
logit or probit model, the resulting value is the
“likelihood” of an individual patient receiving
one treatment over another based on the actual observed treatment method (e.g., Ananthakrishnan et al.24). Once these propensities
are calculated, a matching algorithm is used
to match patients into cohorts based on the
propensity and the actual treatment that was
given—the most common of these algorithms
being nearest-neighbor algorithms, where
“near” observations are grouped together.25 In
an ideal setting, this method is used to develop
random, balanced samples of patients, where
known confounders are considered and relationships between variables of interest can be
examined without compromising the assumptions of parametric statistical methods.

Structural Modeling and GraphAnalytic Approaches

Structural modeling techniques, in conjunction with graph-analytic approaches, serve to
identify the structure in which variables relate
to one another. Particularly, these methods are
useful when confounders are not well-specified, whether from a lack of existing literature
specifying the relationship or in instances
where identifying the confounder is the aim
of the study. These methods are generally
designed to assess or ascertain the structure
of variables by testing linear combinations of
known variables to find the optimal relationships between them. For example, if it were
unclear whether smoking influences hepatic
issues, the structural model would aim to specify whether certain variables, such as BMI or
historical diagnoses of digestive organ issues,
influence the relationship between smoking
and hepatic issues. Similarly, graph-analytic approaches are helpful in visualizing these
relationships when the relationship of interest
involves a large number of confounders, moderators and mediators (e.g., Williams et al.26).
When temporal information is available from
the EHR, such as the progression of diagnoses
in a patient encounter while held inpatient,
methods such as marginal-structure models
can be used to assess the influence of confounders over time by discounting or account-

ing for those variables at certain steps of the
temporal progression. Thus, these methods
may be used to identify and account for nuisance variables when the relationship is unclear,
which can rectify the effects of a lack of randomization and allow for a more valid and reliable assessment of the relationship between
variables of interest.

Principal Component Analysis and
Multidimensional Scaling

The final method to be reviewed in service to
correcting the lack of randomization is data
reduction techniques comprised of methods
such as component analysis (i.e., principal or
independent components analysis; PCA and
ICA, respectively) or multidimensional scaling
(MS). Generally, the goal of these techniques
is to transform datasets, where many variables
are to be considered, into the most informative
and succinct subset of data.27 This method is
ideal in situations where biomarkers or health
characteristics are not well-defined—if it were
the case where we wanted to find specific lab
test values or comorbidities that indicated
septic shock, among a swathe of hundreds of
variables, data reduction techniques allow us
to separate relevant, variance-explaining data
from uninformative data. In particular, component analyses such as PCA or ICA are used to
identify optimal “components” of the data that
maximize the variances that can be accounted for across the entire dataset. Similarly, MS
methods are used to find the optimal dimensions (often 2 or 3 dimensions) that can successfully capture the variability between data
points without sacrificing the meaningfulness
of the differences between observations. These
methods are particularly useful in situations
where the effect of a set of certain variables
are not known and must be established before
the relationships of interest are examined—although, the resulting dimensions identified
in these analyses can be difficult to interpret
when there is no clinical or observable realistic
relationship to be determined. Thus, dimensionality reduction should be reserved for instances when confounders are known but their
relationship between variables of interest are
not known and rather are suspected via clinical
or care-related knowledge.
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The Role of Effect Size in Studies
with Large Sample Sizes

Effect size, which measures magnitude rather
than how rare a statistical difference is, has
been deemed more accurate for gaging statistical significance of a between group difference
than p-values in studies with large sample
sizes.28 It has also been adopted in clinical literature as a more useful to approximate clinical
significance.29 For instance, in a hypothetical
study, a complex, robotically-assisted cardiac
surgery technique is developed to improve
upon a traditional surgical method. The 30-day
mortality of these 2 techniques are compared
retrospectively via a large EHR database using
a chi-squared test. A significant p-value is
obtained, and a manuscript recommending one
technique over the other is written.
What this hypothetical analysis leaves out is
the odds ratio for the comparison was only
0.96, which is a very small difference of only 4%
from the traditional technique. The authors of
the hypothetical analysis would likely not recommend the use of the new surgical technique
given that the investment in teaching the new
technique and buying the machinery might not
be worth a 4% reduction in 30-day mortality.
The use of p-value in hypothesis testing suffers from a fatal flaw. As sample size increases,
p-values become more likely to be significant.
Repeating a 100 patient study with 100,000 patients will result in higher chances of producing
significant p-values, even if the between group
difference is exactly the same. This would
happen because p-value is an indication of
how likely a result is to have come from chance
alone. The larger the sample size, the less likely
a result is to be chance, and thus, lower p-values. That does not mean the result is any more
clinically significant, just that it is unlikely to be
formed by random chance alone.
The use of EHRs commonly results in very large
sample sizes. With the ability to harvest tens
of thousands of patients in some of the larger
hospital network EHRs, traditional statistical
power becomes trivial, and p-values become
far less trustworthy to be the sole determining
factor of significance alone. The p-value should
only be part of the determination of the value of a result in these cases, and researchers
should always be wary of large sample studies
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reporting only a p-value and not the adjoining
effect size.

Conclusion

Despite the numerous limitations outlined in
this paper, the use of EHRs for retrospective
studies presents a valuable opportunity to explore novel research questions that are generally underpowered and unable to be answered
in a prospective research setting. Powerful statistical techniques exist that aid in correcting
these issues related to missing data and lack
of randomization, making EHRs a well-suited
mechanism to evaluate the efficacy of treatments and outcomes in the healthcare setting
and much more.
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